Search Results - "Forci, B."

Clinical activity after fingolimod cessation: disease reactivation or rebound? by Frau, J., Sormani, M. P., Signori, A., Realmuto, S., Baroncini, D., Annovazzi, P., Signoriello, E., Maniscalco, G. T., La Gioia, S., Cordioli, C., Frigeni, B., Rasia, S., Fenu, G., Grasso, R., Sartori, A., Lanzillo, R., Stromillo, M. L., Rossi, S., Forci, B., Cocco, E.

“…Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether…”
Get full text

Safety and efficacy of autologous hematopoietic stem‐cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis by Mariottini, A., Innocenti, C., Forci, B., Magnani, E., Mechi, C., Barilaro, A., Nistri, R., Fani, A., Saccardi, R., Massacesi, L., Repice, A. M.

“…Background and purpose Natalizumab (NTZ) is a highly effective treatment for relapsing‐remitting multiple sclerosis (MS), but its withdrawal is often followed…”
Get full text